Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This locus encodes a long non-coding RNA (lncRNA) that is transcribed antisense to the TSPO gene. There is no current evidence that this antisense transcript functions as a receptor, enzyme, transporter, or known therapeutic target. Its biological function and significance in disease pathways have not been established. It is distinct from the protein-coding TSPO (translocator protein) gene, which is a well-known mitochondrial protein associated with steroidogenesis, apoptosis, and neurodegenerative diseases, but this antisense lncRNA itself is not a canonical drug target. The entry is a valid gene, but as a non-coding antisense RNA, it is not generally recognized as a therapeutic target or classified in major drug target classes. No specific aliases, roles in disease, known functions, or drug interactions are documented in current databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to TSPO.